Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 2/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490742 | 0.92 | CYP1A2 (0.38) | PIK3C2BDCTPP1P2RX3MAPTLMNA | |
| SCHEMBL6489601 | 0.88 | NPSR1 (0.41) | PIK3C2BPTGER1DCTPP1MRGPRX4LMNA | |
| SCHEMBL6488966 | 0.85 | RXRA (0.41) | PIK3C2BDCTPP1MRGPRX4ALOX5APSMN1; SMN2 | |
| SCHEMBL6488103 | 0.85 | P4HTM (0.40) | PIK3C2BDCTPP1MAPTAGTR1TSPO | |
| SCHEMBL6501593 | 0.85 | KDM4C (0.44) | DCTPP1NTRK1 | |
| SCHEMBL6488456 | 0.84 | DCTPP1 (0.44) | DCTPP1TSPO | |
| SCHEMBL6490701 | 0.81 | ALDH1A1 (0.38) | PIK3C2BDCTPP1MAPTALOX5APLMNA | |
| SCHEMBL6487673 | 0.81 | JMJD6 (0.41) | DCTPP1MAPTLMNASMN1; SMN2 | |
| SCHEMBL6489130 | 0.80 | MAPT (0.40) | DCTPP1MAPTLMNASMN1; SMN2TSPO | |
| SCHEMBL6491045 | 0.80 | DCTPP1 (0.42) | DCTPP1MAPTSMN1; SMN2TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PIK3C2B 2433/4885PTGER1 1980/4885PDE4A 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.